Enflonsia, a single-dose, long-acting antibody, has been FDA approved to significantly reduce RSV infections and hospitalizations in infants, providing new hope for protecting vulnerable babies during RSV season.
Macaya Douoguih, MD, MPH
Advertisement
Therapeutic Area Head for Global Vaccine Clinical Development at Merck
Articles by Macaya Douoguih, MD, MPH
Advertisement
Latest Updated Articles
Merck’s Clesrovimab (Enflonsia) Receives FDA Approval to Protect Infants From RSV During First SeasonPublished: June 11th 2025 | Updated: June 11th 2025
Advertisement
Advertisement
Trending on Contagion Live
1
Understanding the Importance of Bird Migration as it Relates to Avian Influenza
2
Rapid HCV Test Provides Opportunity for Single Visit Diagnosis and Treatment Encounters
3
No Negative Impact for Individuals Taking Lenacapavir and Gender-Affirming Hormone Therapy
4
Qpex Biopharma’s New President Wants More Push-Pull Incentives, Opportunities for Young US Scientists
5
